Evidence map›Paper›PMID 31037478›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2019

Correction to: In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.

Irene Galani, Maria Souli, Konstantina Nafplioti, Panagiora Adamou, Ilias Karaiskos, Helen Giamarellou, Anastasia Antoniadou, Study Collaborators

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Irene Galani4th Department of InternalMedicine, Infectious Diseases Laboratory, Molecular Biology Section, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. egalani@med.uoa.gr.ORCID 0000-0001-6455-9848
Maria Souli4th Department of InternalMedicine, Infectious Diseases Laboratory, Molecular Biology Section, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Konstantina Nafplioti4th Department of InternalMedicine, Infectious Diseases Laboratory, Molecular Biology Section, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Panagiora Adamou4th Department of InternalMedicine, Infectious Diseases Laboratory, Molecular Biology Section, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Ilias Karaiskos1st Internal Medicine & Infectious Diseases Clinic, Hygeia General Hospital, Marousi, Greece.
Helen Giamarellou1st Internal Medicine & Infectious Diseases Clinic, Hygeia General Hospital, Marousi, Greece.
Anastasia Antoniadou4th Department of InternalMedicine, Infectious Diseases Laboratory, Molecular Biology Section, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Study Collaborators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The publisher regrets that the article has been published online on 01 March 2019 with errors in Table 1. In the originally published Table 1, the percentage of Imipenem-relebactam susceptibility was incorrectly written as 8 0, while correct data is 98.0. Also, in Meropenem row, column MIC

Identifiers

PMID31037478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.